NCT02953457View on ClinicalTrials.gov

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

September 15, 2021

Study Completion Date

August 15, 2024

Conditions
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
BIOLOGICAL

Durvalumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Olaparib

Given PO

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (2)

10075

The Feinstein Institute for Medical Research/Lennox Hill Hospital, New York

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER